Dose-Dependent Anti-Inflammatory and Neuroprotective Effects of an ανβ3 Integrin-Binding Peptide

Table 2

Histopathological analysis of demyelination damage in spinal cord (S) and brain cortex (B) of C16 dose dependent treated group.

2 weeks	Control 2 w	C16 0.5 mg 2 w; (Low dose group)	C16 1 mg 2 w	C16 2 mg 2 w
Spinal cord	3.60±0.57	1.40±0.56^∗; (𝑃=0.0023 versus control*)	1.39±0.50^∗#; (𝑃=0.001 versus control*; 𝑃=0.039 versus low dose group^#)	0.80±0.45^∗$; (𝑃=0.00013 versus control*; 𝑃=0.006 versus low dose^$)
Brain cortex	3.20±0.44	1.60±0.55^∗; (𝑃=0.001 versus control*)	1.20±0.45^∗#; (𝑃=0.001 versus control*; 𝑃=0.014 versus low dose group^#)	0.60±0.52^∗$; (𝑃=0.0001 versus control*; 𝑃=0.003 versus low dose^$)
8 weeks	Control 8 w	C16 0.5 mg 8 w	C16 1 mg 8 w	C16 2 mg 8 w
Spinal cord	3.40±0.62	2.8±0.84^∗; (𝑃=0.0052 versus control*)	1.8±0.4^∗#; (𝑃=0.0021 versus control*; 𝑃=0.005 versus low dose group^#)	1.2±0.45^∗$; (𝑃=0.0014 versus control*; 𝑃=0.0017 versus low dose^$)
Brain cortex	2.60±0.67	1.4±0.55^∗; (𝑃=0.0018 versus control*)	1.2±0.40^∗#; (𝑃=0.001 versus control*; 𝑃=0.04 versus low dose group^#)	1.0±0.71^∗$; (𝑃=0.0009 versus control*; 𝑃=0.01 versus low dose^$)

Data is presented as Mean ± SD. ^∗𝑃<0.05 was considered statistically significant compared with the control, ^#𝑃<0.05 compared with low dose (0.5 mg) C16 treatment group, and ^$𝑃<0.05 compared with low dose (0.05 mg) C16 treatment group.